Skip to main content
. 2019 May 16;11(5):681. doi: 10.3390/cancers11050681

Figure 4.

Figure 4

Immunohistochemistry with CD3 antibody. (AC) representative photos after different doses of sorafenib treatment in the end of study (Arrow; CD3+ T cell). Scale bar: 100 μm. (D) numbers of CD3+ T cells in tumors (n = 3), * p < 0.05 by Student’s t-test, ns; not significant.